Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib

Molecular Cancer

Volumn 15, Issue 1, 2016, Pages

  Houessinon, Aline ^a,b   François, Catherine ^b   Sauzay, Chloé ^a,b   Louandre, Christophe ^a,b   Mongelard, Gaelle ^b   Godin, Corinne ^a,b   Bodeau, Sandra ^a   Takahashi, Shinichiro ^c   Saidak, Zuzana ^a   Gutierrez, Laurent ^b   Régimbeau, Jean Marc ^a   Barget, Nathalie ^d   Barbare, Jean Claude ^b   Ganne, Nathalie ^d,e,f   Chauffert, Bruno ^b   Coriat, Romain ^g,h   Galmiche, Antoine ^a,b  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c Tohoku Medical and Pharmaceutical University Hospital   (Japan)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITÉ PARIS 13   (France)

^f Université Paris 13   (France)

^g Pole d'Activités Cancérologiques Specialisées ^*  (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Biomarker; Ferroptosis; Hepatocellular carcinoma; Metallothionein 1; Redox metabolism; Sorafenib

Indexed keywords

CYSTEINE; ERLOTINIB; MESSENGER RNA; METALLOTHIONEIN I; RAPAMYCIN; SELUMETINIB; SORAFENIB; TRANSCRIPTION FACTOR NRF2; TUMOR MARKER; VEMURAFENIB; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBANILAMIDE DERIVATIVE; METALLOTHIONEIN; NFE2L2 PROTEIN, HUMAN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

AMINO ACID METABOLISM; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; BASE PAIRING; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE EXPRESSION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MT1G GENE; OVERALL SURVIVAL; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROMOTER REGION; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; LIVER NEOPLASMS; METABOLISM; MORTALITY; PROGNOSIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYSTEINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; METALLOTHIONEIN; NF-E2-RELATED FACTOR 2; NIACINAMIDE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHENYLUREA COMPOUNDS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; TRANSCRIPTION, GENETIC;

EID: 84968854657     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-016-0526-2     Document Type: Article

References (31)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
2. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129-40.
3. Galmiche A, Chauffert B, Barbare JC. New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. Cancer Lett. 2014;346:159-62.
4. Coriat R, Nicco C, Chéreau C, Mir O, Alexandre J, Ropert S, Weill B, Chaussade S, Goldwasser F, Batteux F. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther. 2012;11:2284-93.
5. Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Mazière JC, Chauffert B, Galmiche A. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer. 2013;133:1732-42.
6. Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS, Stockwell BR. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife. 2014;3:e02523.
7. Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, Tang D. Activation of the p62-Keap1-NRF2 Pathway Protects against Ferroptosis in Hepatocellular Carcinoma Cells. Hepatology. 2015. doi: 10.1002/hep.28251. Epub ahead of print.
8. Lachaier E, Louandre C, Godin C, Saidak Z, Diouf M, Chauffert B, Galmiche A. Sorafenib Induces Ferroptosis in Human Cancer Cell Lines Originating from Different Solid Tumours. Anticancer Res. 2014;34:6417-22.
9. Louandre C, Marcq I, Bouhlal H, Lachaier E, Godin C, Saidak Z, François C, Chatelain D, Debuysscher V, Barbare JC, Chauffert B, Galmiche A. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett. 2015;356:971-7.
10. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B 3rd, Stockwell BR. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060-72.
11. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol. 2014;15:135-47.
12. Cao W, Hou FF, Nie J. AOPPs and the progression of kidney disease. Kidney Int Suppl. 2014;4:102-6.
13. Gonzalez E, Bajo MA, Carrero JJ, Lindholm B, Grande C, Sánchez-Villanueva R, Del Peso G, Díaz-Almirón M, Iglesias P, Díez JJ, Selgas R. An Increase of Plasma Advanced Oxidation Protein Products Levels Is Associated with Cardiovascular Risk in Incident Peritoneal Dialysis Patients: A Pilot Study. Oxid Med Cell Longev. 2015;2015:219565.
14. Cherian MG, Jayasurya A, Bay BH. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res. 2003;533:201-9.
15. Haq F, Mahoney M, Koropatnick J. Signaling events for metallothionein induction. Mutat Res. 2003;533:211-26.
16. Ji XF, Fan YC, Gao S, Yang Y, Zhang JJ, Wang K. MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma. World J Gastroenterol. 2014;20:4723-9.
17. Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsuda T, Saijo N. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res. 1991;51:3237-42.
18. Kondo Y, Woo ES, Michalska AE, Choo KH, Lazo JS. Metallothionein null cells have increased sensitivity to anticancer drugs. Cancer Res. 1995;55:2021-3.
19. Arriaga JM, Greco A, Mordoh J, Bianchini M. Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy. Mol Cancer Ther. 2014;13:1369-81.
20. Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc- cystine transporter: a new action for an old drug. Leukemia. 2001;15:1633-40.
21. Wang X, Tomso DJ, Chorley BN, Cho HY, Cheung VG, Kleeberger SR, Bell DA. Identification of polymorphic antioxidant response elements in the human genome. Hum Mol Genet. 2007;16:1188-200.
22. Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci. 2014;39:199-218.
23. Godin C, Dupont S, Ezzoukhry Z, Louandre C, Chatelain D, Henaut L, Sabbagh C, Regimbeau JM, Maziere JC, Barbare JC, Chauffert B, Galmiche A. Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments. Anticancer Res. 2013;33:1415-20.
24. Godin C, Louandre C, Diouf M, Chauffert B, Barbare JC, Barget N, Trinchet JC, Ganne N, Galmiche A. Biomarkers of Apoptotic and Necrotic Cell Death M30/M65 in Patients with Hepatocellular Carcinoma treated by sorafenib. Anticancer Res. 2015;35:1803-8.
25. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12:931-47.
26. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475:106-9.
27. Zavattari P, Perra A, Menegon S, Kowalik MA, Petrelli A, Angioni MM, Follenzi A, Quagliata L, Ledda-Columbano GM, Terracciano L, Giordano S, Columbano A. Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis. Hepatology. 2015;62:851-62.
28. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B, Balabaud C, et al. Integrated analysis of somatic mutations and focal copynumber changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012;44:694-8.
29. Cleary SP, Jeck WR, Zhao X, Chen K, Selitsky SR, Savich GL, Tan TX, Wu MC, Getz G, Lawrence MS, Parker JS, Li J et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology. 2013;58:1693-702.
30. 2 regulates the angiogenic phenotype via PTEN oxidation. J Biol Chem. 2005;280:16916-24.
31. Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, Zhang W, Plunkett W, Huang P. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol. 2006;175:913-23.